ACAD250117P27000
- 12.00
- 0.000.00%
ACADIA Pharmaceuticals Newsroom
ACADIA Pharmaceuticals (ACAD) Receives a Buy From RBC Capital
Mizuho Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Announces Target Price $20
Analysts Conflicted on These Healthcare Names: Avadel Pharmaceuticals (AVDL) and ACADIA Pharmaceuticals (ACAD)
Further Weakness as ACADIA Pharmaceuticals (NASDAQ:ACAD) Drops 5.2% This Week, Taking Five-year Losses to 61%
ACADIA Pharmaceuticals Analyst Ratings
Guggenheim Downgrades ACADIA Pharmaceuticals(ACAD.US) to Hold Rating, Announces Target Price $20
Express News | ACADIA Pharmaceuticals Inc : Guggenheim Cuts Target Price to $20 From $23
Express News | ACADIA Pharmaceuticals Inc : Guggenheim Cuts to Neutral From Buy
Top Midday Gainers
ACADIA Pharmaceuticals Up Over 11%, on Pace for Largest Percent Increase Since December 2023 -- Data Talk
Acadia Pharmaceuticals, FTAI Aviation And Other Big Stocks Moving Higher On Tuesday
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday
Biggest Stock Movers Tuesday: VSTM, ACAD
Buzz - ACADIA Pharmaceuticals will be included in the S&P SmallCap 600 Index, and the stock price is rising.
On December 30, ACADIA Pharmaceuticals (ACAD.O) saw a rise of 9.35% in after-hours trading, at $18.25. Standard & Poor's Dow Jones Indices announced after the close on Monday that ACADIA Pharmaceuticals would replace Independent Bank Group (IBTX.O) as a member of the S&P SmallCap 600 Index. Out of 19 Brokerages, 13 rated ACAD as "Buy" or higher, 5 as "Hold", and 1 as "Sell"; its median price target is $26 -- LSEG data.
Acadia Pharmaceuticals Set to Join S&P SmallCap 600
Express News | S&P Dow Jones Indices: ACADIA Pharmaceuticals to Replace Independent Bank Group in S&P Smallcap 600
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | ACADIA Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)